Eindhoven-based MedTech trailblazer, Microsure, has just secured a whopping €38 million in a Series B2 funding round, marking a significant milestone for the company. In a stellar line-up of investors, the European Innovation Council Fund (EICF), kineo, Invest-NL, and several prominent private investor groups have thrown their weight behind Microsure. Not to forget the steadfast support of existing shareholders such as Innovation Industries and Eindhoven University of Technology.
The funding influx sets the stage for Microsure to put the finishing touches on its groundbreaking microsurgical robot, MUSA-3, paving the way for clinical studies, FDA clearance in the USA, and CE-mark approval in Europe. As part of this financing coup, Kreske Nickelsen from kineo will join Microsure’s supervisory board, bolstering the company's governance.
Prominent microsurgery expert, Professor Peter Neligan, lauds Microsure's pioneering innovations, hailing them as transformative for the field of microsurgery. He believes that Microsure's unwavering commitment to precision and groundbreaking technologies will reshape microsurgical techniques, ultimately leading to significantly improved patient outcomes.
Svetoslava Georgieva, Chair of the EIC Fund Board, expresses optimism about Microsure's potential to make a profound impact on patients in need of microsurgery. With this latest funding, the company is poised to introduce MUSA-3 to EU markets, marking a significant leap forward.
Sjaak Deckers, Microsure's CEO, extends his gratitude to both new and existing investors, acknowledging their unwavering support. The funds secured will empower Microsure to advance its groundbreaking technology and provide innovative solutions to patients worldwide through the MUSA-3 robotic system.
Founded in 2016 by Raimondo Cau and Tom Van Mulken, Microsure has been a driving force in the realm of microsurgery. MUSA-3, their cutting-edge microsurgical robot, is set to redefine the field of open microsurgery, equipping microsurgeons with unprecedented precision, stability, and control. It promises to elevate patient care to new heights, offering tremor reduction, seamless integration with surgeons' preferred micro-instruments, and adaptability for a wide range of surgical procedures.
MUSA-3 combines surgeon comfort with improved ergonomics, enabling surgeons to work from a console with digital exoscopes or hybrid surgical microscopes. This funding round marks a remarkable step forward for Microsure and the future of microsurgery.
